RARE shares plunge after Angelman late-stage trial failure, downgraded
Ultragenyx Pharmaceutical’s experimental Angelman syndrome therapy failed a key late-stage trial, triggering analyst downgrades and fresh concerns. RARE shares were down 45% in pre-market trading.